AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
Enfortumab Vedotin Plus Pembrolizumab Reshapes Bladder Cancer, From Metastatic Disease to Surgery
By David VanderWeele, MD, PhD
For decades, platinum-based chemotherapy (cisplatin- or carboplatin-based regimens combined with gemcitabine) was the mainstay of treatment for metastatic urothelial cancer, with little improvement from added agents.
Enfortumab Vedotin Plus Pembrolizumab Reshapes Bladder Cancer, From Metastatic Disease to Surgery
By David VanderWeele, MD, PhD
For decades, platinum-based chemotherapy (cisplatin- or carboplatin-based regimens combined with gemcitabine) was the mainstay of treatment for metastatic urothelial cancer, with little improvement from added agents.
Enfortumab Vedotin Plus Pembrolizumab Reshapes Bladder Cancer, From Metastatic Disease to Surgery
By David VanderWeele, MD, PhD
For decades, platinum-based chemotherapy (cisplatin- or carboplatin-based regimens combined with gemcitabine) was the mainstay of treatment for metastatic urothelial cancer, with little improvement from added agents.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Head and Neck Cancer: New Antibodies After Checkpoint Failure, and Rethinking Immunotherapy Plus Radiation
By Weining Ken Zhen, MD
Developing new strategies for advanced head and neck cancer after checkpoint inhibitor and chemotherapy failures.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Kidney Cancer: Conflicting Adjuvant Immunotherapy Data and a Real Option for Non-Clear Cell Disease
By Benjamin A. Teply, MD
We have yet to have truly confirmatory data for a benefit for adjuvant immunotherapy in kidney cancer.
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Colorectal Cancer: Exercise Pays Off, Aspirin's Role Stays Murky, Some Can Stop Immunotherapy Early
By Rishi Batra, MD, MBA
Three abstracts from this year's ASCO meeting speak to very different parts of the colorectal cancer journey
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Gastrointestinal Cancer Updates From the Best of GI Oncology 2026
By Haadi Ali, MD ; Ibrahim Halil Sahin, MD
Daraxonrasib is an orally administered, multiselective RAS(ON) inhibitor designed to target the active, GTP-bound state of multiple mutant and wild-type RAS proteins.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Tarlatamab for Small Cell Lung Cancer: How DLL3-Targeted Therapy Works
By Daniel Ricardo Carrizosa, MD, MS
Small cell lung cancer has long been considered one of the more difficult diagnoses in thoracic oncology.
Tarlatamab for Small Cell Lung Cancer: How DLL3-Targeted Therapy Works
By Daniel Ricardo Carrizosa, MD, MS
Small cell lung cancer has long been considered one of the more difficult diagnoses in thoracic oncology.
Tarlatamab for Small Cell Lung Cancer: How DLL3-Targeted Therapy Works
By Daniel Ricardo Carrizosa, MD, MS
Small cell lung cancer has long been considered one of the more difficult diagnoses in thoracic oncology.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
A New Antibody-Drug Conjugate and a Biomarker Reality Check for Small Cell Lung Cancer
By Mark Alan Klein, MD
Small cell lung cancer has trailed its non-small cell counterpart in new drug approvals for years, and at this year's ASCO meeting there were no studies presented that affect first-line treatments at this time.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
Triple Negative Breast Cancer Gets Real Momentum: What ASCO 2026 Changes for Patients Now
By Amulya Yellala, MD
Triple negative breast cancer has long been described as hard to treat and fast moving, but this year's data, much of it long-term follow-up on treatments already reshaping practice, continues to build real momentum.
CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia
By Thomas Knight, MD
Ten years ago, ALL was a chemotherapy-heavy disease with poor long-term survival for many patient groups. That has changed dramatically.
CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia
By Thomas Knight, MD
Ten years ago, ALL was a chemotherapy-heavy disease with poor long-term survival for many patient groups. That has changed dramatically.
CAR-T Cell Therapy and Bispecific Antibodies Are Transforming Acute Lymphoblastic Leukemia
By Thomas Knight, MD
Ten years ago, ALL was a chemotherapy-heavy disease with poor long-term survival for many patient groups. That has changed dramatically.